Good morning and welcome everyone to the Liquidia Corporation full year 2024 financial result and corporate update conference call. My name is Shannon, and I will be your conference operator today.

Corsair Pharma is planning a Phase 1 clinical trial of its treprostinil skin patch as a treatment for pulmonary arterial hypertension (PAH).

BofA lowered the firm’s price target on United Therapeutics (UTHR) to $314 from $328 and keeps an Underperform rating on the shares. The firm ...

To date, participants have safely titrated to the study’s maximum dose twice daily, which is comparable to 26-28 breaths of Tyvaso® administered four times per day. The FDA has confirmed that a single ...

Proficio Capital Partners LLC bought a new stake in United Therapeutics Co. (NASDAQ:UTHR – Free Report) during the fourth ...

Despite the unfavorable ruling for Liquidia, the regulatory exclusivity period for Tyvaso DPI is still set to expire on May 23, 2025. Additionally, United Therapeutics had filed a cross claim in the ...

The FDA was right to delay final approval of Liquidia Corp.'s lung-disease drug Yutrepia due to United Therapeutics Corp.'s exclusivity rights for the dry-powder-inhalation version of its blockbuster ...

United Therapeutics’ Q4 earnings brought clarity on the outlook for the base commercial business and Tyvaso’s future growth trajectory, suggesting that gross-to-net impact from recent ...